FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601840805> ?p ?o ?g. }

• W2601840805 abstract "e20600 Background: Breast and arm cellulitis (BAC) is a recognized risk following treatment for early stage breast cancer with case reports suggesting an incidence <3%. However, there is limited information relative to risk factors, management, recurring BAC and outcome. We reviewed all incidences of BAC in patients (pts) with early stage breast cancer seen at our institution and correlate with co-morbid conditions, recurrent BAC events and treatment outcomes. Methods: A review of all pts with Stage I-III breast cancer seen between 2001-2011 identified pts with at least 1 episode of BAC. Data on age, race, stage, treatments, co-morbid conditions, lymphedema, incidence and recurrence of cellulitis, and antibiotic (Abx) therapy was extracted. We defined incident BAC to occur >30 days post chemotherapy/radiation completion. Chi-square test was used to assess variables associated with BAC recurrence. Results: 391,603 breast cancer pts (2.5%) were identified with BAC with median age 59 years. The median interval between completion of primary treatment and incident cellulitis was 330 days (30 – 3,650 days). 13 out of 39 pts (33%) had recurring BAC (range 1-7 events). Median duration of Abx therapy was 30 days (7 – 2,190). Lymphedema (p=0.04), chemotherapy (p=0.01), Stage > I (p=0.02) and initial poor response to Abx (p=0.003) were significantly associated with recurring BAC. Positive bacterial cultures were obtained in 4 of 62 BAC events. Initial Abx failure was lowest with vancomycin (Vanc). A protracted course (30 days) of oral Abx after initial Vanc was associated with a lower risk of early recurrence. Chronic Abx therapy, for pts with 3 episodes, appeared to reduce subsequent recurrent episodes. Conclusions: Results indicate that while BAC is relatively uncommon following breast cancer therapy, pts with BAC are at significant risk for recurring events. Lymphedema, higher stage and initial poor response to Abx proofed as parameters for recurrence. Despite treatment with Abx a significant number will have recurring events. For pts presenting with these variables we recommend a protracted course of initial Abx. Pts with recurring BAC should receive chronic Abx suppressive therapy. This approach was associated with good long term control in our pts." @default.
• W2601840805 created "2017-04-07" @default.
• W2601840805 creator A5023195809 @default.
• W2601840805 creator A5028365944 @default.
• W2601840805 creator A5042858506 @default.
• W2601840805 creator A5048566920 @default.
• W2601840805 creator A5049051758 @default.
• W2601840805 creator A5062197967 @default.
• W2601840805 creator A5073696926 @default.
• W2601840805 creator A5079958823 @default.
• W2601840805 creator A5085652298 @default.
• W2601840805 date "2013-05-20" @default.
• W2601840805 modified "2023-09-27" @default.
• W2601840805 title "Recurring breast and arm cellulitis in patients with early breast cancer." @default.
• W2601840805 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e20600" @default.
• W2601840805 hasPublicationYear "2013" @default.
• W2601840805 type Work @default.
• W2601840805 sameAs 2601840805 @default.
• W2601840805 citedByCount "1" @default.
• W2601840805 countsByYear W26018408052020 @default.
• W2601840805 crossrefType "journal-article" @default.
• W2601840805 hasAuthorship W2601840805A5023195809 @default.
• W2601840805 hasAuthorship W2601840805A5028365944 @default.
• W2601840805 hasAuthorship W2601840805A5042858506 @default.
• W2601840805 hasAuthorship W2601840805A5048566920 @default.
• W2601840805 hasAuthorship W2601840805A5049051758 @default.
• W2601840805 hasAuthorship W2601840805A5062197967 @default.
• W2601840805 hasAuthorship W2601840805A5073696926 @default.
• W2601840805 hasAuthorship W2601840805A5079958823 @default.
• W2601840805 hasAuthorship W2601840805A5085652298 @default.
• W2601840805 hasConcept C121608353 @default.
• W2601840805 hasConcept C126322002 @default.
• W2601840805 hasConcept C141071460 @default.
• W2601840805 hasConcept C143998085 @default.
• W2601840805 hasConcept C2777238321 @default.
• W2601840805 hasConcept C530470458 @default.
• W2601840805 hasConcept C71924100 @default.
• W2601840805 hasConceptScore W2601840805C121608353 @default.
• W2601840805 hasConceptScore W2601840805C126322002 @default.
• W2601840805 hasConceptScore W2601840805C141071460 @default.
• W2601840805 hasConceptScore W2601840805C143998085 @default.
• W2601840805 hasConceptScore W2601840805C2777238321 @default.
• W2601840805 hasConceptScore W2601840805C530470458 @default.
• W2601840805 hasConceptScore W2601840805C71924100 @default.
• W2601840805 hasLocation W26018408051 @default.
• W2601840805 hasOpenAccess W2601840805 @default.
• W2601840805 hasPrimaryLocation W26018408051 @default.
• W2601840805 hasRelatedWork W1160658 @default.
• W2601840805 hasRelatedWork W1567374451 @default.
• W2601840805 hasRelatedWork W1935319718 @default.
• W2601840805 hasRelatedWork W1989012207 @default.
• W2601840805 hasRelatedWork W1997678564 @default.
• W2601840805 hasRelatedWork W2027498177 @default.
• W2601840805 hasRelatedWork W2027940838 @default.
• W2601840805 hasRelatedWork W2075833131 @default.
• W2601840805 hasRelatedWork W2181567891 @default.
• W2601840805 hasRelatedWork W2186748231 @default.
• W2601840805 hasRelatedWork W2298477572 @default.
• W2601840805 hasRelatedWork W2313185116 @default.
• W2601840805 hasRelatedWork W2372703718 @default.
• W2601840805 hasRelatedWork W2416230667 @default.
• W2601840805 hasRelatedWork W2418895916 @default.
• W2601840805 hasRelatedWork W2607133987 @default.
• W2601840805 hasRelatedWork W2942469321 @default.
• W2601840805 hasRelatedWork W3130661798 @default.
• W2601840805 hasRelatedWork W3155759827 @default.
• W2601840805 hasRelatedWork W2336090284 @default.
• W2601840805 isParatext "false" @default.
• W2601840805 isRetracted "false" @default.
• W2601840805 magId "2601840805" @default.
• W2601840805 workType "article" @default.